InMed Pharmaceuticals Inc. Files 8-K: Material Agreement & Equity Sales

TL;DR

InMed Pharma inked a big deal and sold some stock on Dec 13th. 8-K filed.

AI Summary

InMed Pharmaceuticals Inc. announced on December 13, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and provided a Regulation FD disclosure. This filing includes financial statements and exhibits related to these events.

Why It Matters

This 8-K filing indicates significant corporate activity for InMed Pharmaceuticals, including a new material agreement and equity transactions, which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing involves a material definitive agreement and unregistered sales of equity, which can introduce financial and regulatory risks.

Key Players & Entities

• InMed Pharmaceuticals Inc. (company) — Filer
• December 13, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $10 million — the right to sell to the Investor up to $10 million in the aggregate (the "Commitment Amoun
• $1 million — ) such number of Common Shares equal to $1 million as of the date of each Advance Notice (
• $25,000 — stor a structuring fee in the amount of $25,000 and agreed to pay the Investor a commit

Filing Documents

• ea0225022-8k_inmed.htm (8-K) — 38KB
• ea022502201ex10-1_inmed.htm (EX-10.1) — 283KB
• ea022502201ex99-1_inmed.htm (EX-99.1) — 11KB
• ex99-1_001.jpg (GRAPHIC) — 5KB
• 0001213900-24-109891.txt ( ) — 571KB
• inm-20241213.xsd (EX-101.SCH) — 3KB
• inm-20241213_lab.xml (EX-101.LAB) — 33KB
• inm-20241213_pre.xml (EX-101.PRE) — 22KB
• ea0225022-8k_inmed_htm.xml (XML) — 4KB

01 Entry Into a Material Definitive Agreement

Item 1.01 Entry Into a Material Definitive Agreement. On December 13, 2024, InMed Pharmaceuticals Inc. (the "Company") entered into that certain Standby Equity Purchase Agreement ("SEPA") with YA II PN, LTD, a Cayman Islands exempt limited partnership (the "Investor"), pursuant to which the Company has the right to sell to the Investor up to $10 million in the aggregate (the "Commitment Amount") of its common shares, no par value (the "Common Shares"), subject to certain limitations and conditions set forth in the SEPA, from time to time during the commitment term of the SEPA. Sales of the Common Shares to the Investor under the SEPA, and the timing of any such sales, are at the Company's option and discretion, and the Company is under no obligation to sell any of its Common Shares to the Investor under the SEPA. Upon the satisfaction of the conditions to the Investor's purchase obligation set forth in the SEPA, including having a registration by the United States Securities and Exchange Commission, the Company will have the right, but not the obligation, from time to time at its discretion (until the SEPA is terminated) to direct the Investor to purchase a specified number of Common Shares (in each case, an "Advance") by delivering written notice to the Investor ( "Advance Notice"). While there is no mandatory minimum amount for any Advance, it may not exceed the "Maximum Advance Amount," which is defined in the SEPA as the lower of: (i) an amount equal to one hundred percent (100%) of the average of the Daily Traded Amount during each of the five (5) Trading Days immediately preceding an Advance Notice, or (ii) such number of Common Shares equal to $1 million as of the date of each Advance Notice (determined based on the last closing price of the Common Shares on the Principal Market prior to delivery of such Advance Notice or such oth

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. The Investor represented to the Company in the SEPA, among other things, that it is an "accredited investor" (as such term is defined in Rule 501(a) of Regulation D under the Securities Act). The Common Shares referred to in this Current Report on Form 8-K, once issued and sold, are being issued and sold by the Company to the Investor in reliance upon the exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and/or the safe harbor set forth under Rule 506 of Regulation D of the Securities Act. The Common Shares referred to in Item 1.01 of this Current Report on Form 8-K have not been registered under the Securities Act and may not be offered or sold in the United States in the absence of an effective registration statement or exemption from the registration requirements.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 17, 2024, the Company issued a press release announcing that the Company had entered into the SEPA with the Investor. The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 10.1 Standby Equity Purchase Agreement, dated December 13, 2024, between InMed Pharmaceuticals Inc. and YA II PN, Ltd. 99.1 News release, dated December 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: December 17, 2024 By: /s/ Eric A Adams Eric A Adams President & CEO 3

View Full Filing

View this 8-K filing on SEC EDGAR